Study summary
Immunotherapy before surgery beat surgery first for stage III melanoma
83.7%event-free at 12 months, vs 57.2% with surgery first
What was tested
Two doses of nivolumab plus ipilimumab before surgery, against surgery followed by immunotherapy, for stage III melanoma that can be removed.
What they found
- Event-free survival at 12 months was 83.7% vs 57.2%.
- Many people who responded well needed no further treatment after surgery.
What it means
Shifts stage III melanoma toward treatment before surgery; the tumor still in place helps prime the immune system.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.